Fareeha Siddiqui, MD
Hematology & Oncology · San Diego, CANPI 1104848720
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $336 of the $543 with a category attached, or 61.9%. 10 manufacturers reported payments, led by Amgen at 29.3% of the total. Reporting peaked in 2020 at $175 and has fallen 83.9% since, to $28 in 2024. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 18 payments — averaging $30.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$159
- Lilly USA, LLC$107
- Rigel Pharmaceuticals, Inc.$66
- E.r. Squibb & Sons, L.L.C.$62
- Gilead$34
- Pfizer$31
- plus $84 from 4 others
What the payments were for
- Food & beverage$33662%
- Education$20738%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 5 | $159 |
| Lilly USA, LLC | 1 | $107 |
| Rigel Pharmaceuticals, Inc. | 1 | $66 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Gilead | 2 | $34 |
| Pfizer | 2 | $31 |
| Array Biopharma Inc | 1 | $30 |
| Karyopharm Therapeutics Inc. | 1 | $20 |
| GSK | 1 | $18 |
| Incyte Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RETEVMO$107
How this compares
$543 in reported general payments places this provider in the 25th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 36 | $579,998 |
| RevlimidLenalidomide | 25 | $477,881 |
| Zileuton ErZileuton | 178 | $451,060 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 245 | $320,395 |
| TagrissoOsimertinib Mesylate | 15 | $236,989 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 32 | $132,234 |
| EliquisApixaban | 201 | $131,808 |
| JardianceEmpagliflozin | 201 | $126,764 |
| Metformin Er GastricMetformin Hcl | 59 | $116,265 |
| JanuviaSitagliptin Phosphate | 195 | $113,219 |
| OzempicSemaglutide | 82 | $79,870 |
| SprycelDasatinib | 13 | $73,161 |
| TivicayDolutegravir Sodium | 19 | $58,945 |
| LinzessLinaclotide | 98 | $53,013 |
| JulucaDolutegravir/Rilpivirine | 11 | $39,888 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $34 | $157,26243 claims |
| PfizerEliquis | $31 | $131,808201 claims |
| Lilly USA, LLCMounjaro, Trulicity | $107 | $78,25971 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $62 | $73,16113 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $18 | $64,480122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in San Diego
- Wendy LevinSan Diego$760K
- Rana McKaySan Diego$530K
- Ezra CohenSan Diego$495K
- Annette von DrygalskiSan Diego$406K
- Lyudmila BazhenovaSan Diego$328K
- Sandip PatelSan Diego$295K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.